Publication:


abstract

High levels of reactive oxygen species (ROS) are observed in chronic human diseases such as obesity, type 2 diabetes, atherosclerosis, and cardiovascular diseases. In addition to the presence of oxidative stress, these diseases are also characterized by deregulated inflammatory responses. Our first aim is to discuss distinct molecular pathways that determine the rate of Mitochondrial ROS (mtROS) production and identify agents and enzymes that disrupt the balance between ROS generation and ROS elimination. Recent studies exploring the mechanisms linking ROS and inflammation found that ROS derived from mitochondria act as signal-transducing molecules that provoke endothelial dysfunction associated with uncoupling of nitric oxide synthase, induce the infiltration and activation of inflammatory cells, and increase apoptosis of endothelial and vascular smooth muscle cells. Therefore, our second aim is to give a comprehensive overview of the role of mtROS in all these processes contributing to atherosclerotic lesion progression and causing plaque erosion and rupture. Our third aim is to emphasize the role of the inflammatory toll-like receptor 2/NF-κB signaling pathway in the induction of pro-inflammatory cytokines and mtROS production in relation to insulin resistance, type 2 diabetes, and atherosclerosis. Because mtROS play an active role in several pathogenic mechanisms there is need for mitochondria-targeted antioxidants. Preliminary experiments in cell and animal models of cardiovascular diseases showed that some mitochondria-targeted antioxidants indeed reduce ROS production. However, wide-spread use in humans requires the development of specific and sensitive assays to evaluate mitochondrial oxidative stress and the development of orally active compounds.

Related Articles
Review Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy.
Curr Med Chem. 2009
Review Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy.
Victor VM, Apostolova N, Herance R, Hernandez-Mijares A, Rocha M. Curr Med Chem. 2009; 16(35):4654-67.
Review Mitochondrial reactive oxygen species drive proinflammatory cytokine production.
J Exp Med. 2011
Review Mitochondrial reactive oxygen species drive proinflammatory cytokine production.
Naik E, Dixit VM. J Exp Med. 2011 Mar 14; 208(3):417-20. Epub 2011 Feb 28.
Review Fetal programming of atherosclerosis: possible role of the mitochondria.
Eur J Obstet Gynecol Reprod Bi...
Review Fetal programming of atherosclerosis: possible role of the mitochondria.
Leduc L, Levy E, Bouity-Voubou M, Delvin E. Eur J Obstet Gynecol Reprod Biol. 2010 Apr; 149(2):127-30. Epub 2010 Jan 6.
Regulatory role of mitochondria in oxidative stress and atherosclerosis.
World J Cardiol. 2010
Regulatory role of mitochondria in oxidative stress and atherosclerosis.
Chang JC, Kou SJ, Lin WT, Liu CS. World J Cardiol. 2010 Jun 26; 2(6):150-9.
Review [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in metabolic disorders: hypercholesterolaemia and diabetes].
Drugs. 2002
Review [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in metabolic disorders: hypercholesterolaemia and diabetes].
Strawn WB. Drugs. 2002; 62 Spec No 1:31-41.